Depression Treatment: Lifestyle-Oriented Non-Pharmacological Treatments for Fibromyalgia: A Clinical Overview and Applications With Home-Based Technologies.

Lifestyle-oriented non-pharmacological treatments for fibromyalgia: a clinical overview and applications with home-based technologies.

Filed under: Depression Treatment

J Pain Res. 2012; 5: 425-35
Friedberg F, Williams DA, Collinge W

Fibromyalgia (FM) is a persistent and disabling widespread pain condition often accompanied by chronic fatigue, cognitive problems, sleep disturbance, depression, anxiety, and headache. To date, the most thoroughly studied non-pharmacological approaches to managing FM are those with a focus on changing patient activities and beliefs that affect the illness. These interventions are intended to facilitate enduring improvement in pain and functional status. Lifestyle-oriented treatments include patient education, aerobic or other physical exercise, and cognitive-behavioral therapy (CBT). These interventions in FM can be delivered in medical or behavioral health care settings by trained professionals, through patient-oriented treatment manuals, or via remote-access technologies. Non-pharmacological treatments, in particular exercise and CBT, have yielded effect sizes and cost-benefit ratios comparable to medications. This paper describes lifestyle-oriented non-pharmacological treatments for FM and highlights selected literature reviews of these interventions. In addition, behavioral and practical issues are addressed that may affect these non-pharmacological treatments, including patient expectations, participant burden, and treatment availability. Recommendations are made to facilitate these interventions and potentially improve outcomes. In particular, the increasing availability of convenient home-based mobile technologies to deliver these non-pharmacological treatments is described.
HubMed – depression

 

Predictors of Persistence After a Positive Depression Screen Among Adolescents.

Filed under: Depression Treatment

Pediatrics. 2012 Nov 19;
Richardson LP, McCauley E, McCarty CA, Grossman DC, Myaing M, Zhou C, Richards J, Rockhill C, Katon W

OBJECTIVE:To examine predictors of depression persistence after a positive screening test to inform management protocols for screened youth.METHODS:We conducted a cohort study of 444 youth (aged 13-17 years) from a large health care delivery system. Youth with depressive symptoms, based on a 2-item depression screen, were oversampled for the baseline interview. Baseline assessments included the Patient Health Questionnaire 9-item (PHQ-9) depression screen as well as clinical factors that were hypothesized to influence depression persistence (family history of depression, functional impairment, perceived social support, anxiety symptoms, externalizing symptoms, and medical comorbidity). Logistic regression analysis was used to examine factors associated with the persistence of depression at 6 months postbaseline.RESULTS:Of 113 youth with a positive baseline screen (PHQ-9 ?11), 47% and 35% continued to be positive at 6-week and 6-month follow-up, respectively. After controlling for treatment status, only 2 factors were significantly associated with depression persistence at 6 months: baseline depressive symptom score and continuing to have a positive screen at 6 weeks. For each 1-point increase on the PHQ-9 score at baseline, youth had a 16% increased odds of continuing to be depressed at 6 months (odds ratio: 1.16, 95% confidence interval: 1.01-1.34). Youth who continued to screen positive 6 weeks later had almost 3 times the odds of being depressed at 6 months (odds ratio: 2.89, 95% confidence interval: 1.09-7.61).CONCLUSIONS:Depressive symptom severity at presentation and continued symptoms at 6 weeks postscreening are the strongest predictors of depression persistence. Patients with high depressive symptom scores and continued symptoms at 6 weeks should receive active treatment.
HubMed – depression

 

Leishmania amastigotes in the central nervous system of a naturally infected dog.

Filed under: Depression Treatment

J Vet Diagn Invest. 2012 Nov 19;
Márquez M, Pedregosa JR, López J, Marco-Salazar P, Fondevila D, Pumarola M

A 4-year-old male Labrador Retriever dog was presented with a 10-day history of tetraplegia, depression, and absent postural reflexes. The cerebrospinal fluid was positive for Leishmania spp. DNA. At necropsy, a 2-cm long mass was observed adhered to C(7) and C(8) left spinal nerves. Microscopically, nerve fiber destruction together with mixed inflammatory infiltration was observed in the spinal nerves. Cervical spinal cord sections showed multifocal, diffuse granulomatous inflammation in the white matter. In the brain, perivascular infiltrates were observed in some areas together with subtle pallor of the parenchyma. Immunohistochemistry for Leishmania infantum confirmed the presence of amastigotes in the spinal nerves, spinal cord, brain parenchyma, and choroid plexuses. The current study describes the presence of Leishmania amastigotes in nervous tissue inciting radiculoneuritis, myelitis, and mild meningoencephalitis, suggesting a likely route by which L. infantum amastigotes reach and affect the central nervous system parenchyma.
HubMed – depression

 

Depression Treatment

$699.99
End Date: Friday Dec-13-2019 22:15:18 PST
Buy It Now for only: $699.99
Buy It Now | Add to watch list

 

Complete Depression Treatment
$36.76
End Date: Thursday Nov-28-2019 9:25:58 PST
Buy It Now for only: $36.76
Buy It Now | Add to watch list

 

Depression Treatment: How to Live a Happy Life Depression Free - Depression and
$14.27
End Date: Saturday Dec-14-2019 4:13:28 PST
Buy It Now for only: $14.27
Buy It Now | Add to watch list

 

More Depression Treatment Information…